From 2022 to 2031 the worldwide Antimicrobial Susceptibility Testing market is expected to expand at a CAGR of 5.0%. USD 3.2 billion is the market size in 2022; by 2031 it is predicted to have risen to USD 5.9 billion. Thanks in large part to sophisticated healthcare infrastructure and great acceptance of automated AST systems, North America today dominates the industry.
Rising incidence of infectious illnesses, developing antibiotic resistance, and increased awareness of the need of early and precise diagnosis are driving notable expansion of the market. Rapid and automated systems as well as technological developments in AST techniques are driving market growth even further.
Market Trend Shift towards quick and more accurate findings via rapid and automated AST systems
Rapid and automated AST systems are clearly driving a trend in antimicrobial susceptibility testing industry. Faster turnaround times, better accuracy, and less work needed are just a few of the various benefits these sophisticated technologies provide over conventional hand techniques. By allowing findings in hours instead of days, automated technologies help doctors to make quick treatment choices and thereby enhance patient outcomes. These systems also typically interface with laboratory information systems, therefore optimizing processes and lowering the possibility of human mistake. High-volume clinical labs and hospitals where accuracy and efficiency are critical show very strong trends in this regard. Adoption of fast and automated AST systems is projected to hasten as healthcare institutions give antimicrobial stewardship programs top priority and fight the growing problem of antibiotic resistance top importance. This will help to drive market expansion in the next years.
Market Motive Increasing frequency of infectious illnesses and growing antibiotic resistance
Main forces driving the antimicrobial susceptibility testing market forward are the rising frequency of infectious disorders and the growing danger of antibiotic resistance. Globally, infectious illnesses remain a major source of morbidity and death; novel pathogens and the revival of old ones provide continuous difficulties for public health. Concurrent with their overuse and abuse, resistant strains of bacteria have evolved from which many traditional therapies are useless. This double difficulty has made accurate and prompt antimicrobial susceptibility testing even more important for direction of suitable antibiotic treatment. AST findings are becoming more and more important for healthcare professionals choosing the best antimicrobial drugs, adjusting dose schedules, and reducing treatment failure risk. Furthermore underlined by regulatory authorities and health groups throughout the globe is the requirement of strong antimicrobial stewardship programs, which by nature rely on accurate AST data. Demand for improved AST technologies and services is therefore rising, which is generating significant market expansion in many different healthcare environments.
Market Restrain High expenses related to modern AST systems and dearth of qualified experts
Although antimicrobial susceptibility testing is in more demand than ever, the industry is severely limited by the high expenses connected to modern AST equipment and a scarcity of qualified practitioners. Although they have many advantages, advanced automated AST systems can have high initial out-of-pocket expenditures and continuous maintenance requirements. Smaller labs and healthcare institutions in resource- constrained environments may find this cost barrier especially difficult, therefore perhaps restricting market penetration in certain areas. Besides, running these advanced systems calls for certain knowledge and experience. Trained microbiologists and laboratory personnel skilled in analyzing complicated AST data and troubleshooting modern equipment are conspicuously rare. This skills gap can cause certain facilities to avoid using more modern AST techniques and result in underutilization of the current technology. Particularly in developing countries where healthcare resources are often limited, the combination of high prices and personnel constraints might hinder the pace of industry expansion.
Seldom seen on the market is automated AST systems. providing in antimicrobial susceptibility testing quick results and enhanced accuracy
Driven by its fast and precise findings, the Automated AST Systems segment now dominates the antimicrobial susceptibility testing market. Higher throughput, standardized processes, and less human error among other benefits these technologies provide over hand approaches. High-volume clinical labs would find automated systems perfect as they can handle a lot of samples concurrently. They also fit very well with laboratory information systems, therefore enhancing general productivity. Further contributing to the segment's predominance are the increasing focus on antimicrobial stewardship initiatives and the requirement of fast, accurate AST results in critical care environments. The automated AST systems segment is projected to keep its dominant position in the market as healthcare facilities give fast diagnostics top priority in guiding proper antibiotic treatment more and more importance.
North America dominates the market because of its modern healthcare system and great acceptance of automated solutions
Driven by numerous important variables, North America now controls the worldwide antimicrobial susceptibility testing industry. The area features modern healthcare facilities with reputable clinical labs and hospitals furnished with cutting-edge diagnostic equipment. Particularly in the United States, where healthcare institutions give fast and reliable diagnoses top priority to assist antimicrobial stewardship initiatives, automated AST systems are very popular in North America. Major market players and continual research and development efforts in the area help to drive constant technical developments in AST techniques. Furthermore driving market expansion are advantageous reimbursement rules and growing knowledge of the need of using the right antibiotics. The need for dependable AST solutions also stems from the strict regulatory environment of the area and focus on quality healthcare provision. Antimicrobial resistance is a major issue for North America, therefore the market for antimicrobial susceptibility testing is likely to keep its robust development path in the next years.
Intense rivalry among many major players and an increasing number of startups define the antimicrobial susceptibility testing industry. Established global companies with a range of products compete with specialist companies focused only on AST technology. To provide new AST solutions, enhance current goods, and increase their geographical presence, the industry leaders are always funding research and development. Common activities as businesses try to improve their technical capacity and market dominance include strategic alliances, mergers, and acquisitions. To satisfy the rising need for speedier findings, development of quick, automated systems and point-of-care testing solutions is under more and more importance. Companies are also concentrating on growing their footprint in developing nations and creating reasonably priced answers to meet the demands of environments with limited resources. Regulatory restrictions also help to define the competitive scene as businesses try to satisfy strict quality criteria and get required licenses for their AST goods.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Antimicrobial Susceptibility Testing Market (2018 – 2022)
3.2. Global Antimicrobial Susceptibility Testing Market (2023 – 2031)
3.2.1. Market Segment By Test Type (2023 – 2031)
3.2.2. Market Segment By Application (2023 – 2031)
3.2.3. Market Segment By End User (2023 – 2031)
3.2.4. Market Segment By Region (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Shift towards rapid and automated AST systems for faster and more accurate results
4.1.2. Integration of artificial intelligence and machine learning in AST analysis
4.1.3. Growing focus on developing AST methods for difficult-to-treat pathogens
4.2. Market Drivers
4.2.1. Rising prevalence of infectious diseases and growing antibiotic resistance
4.2.2. Increasing emphasis on antimicrobial stewardship programs
4.2.3. Technological advancements in AST methods and systems
4.3. Market Restraints
4.3.1. High costs associated with advanced AST systems and lack of skilled professionals
4.3.2. Limited standardization of AST methods across different regions
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY TEST TYPE (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Automated AST Systems
5.2. Manual AST Methods
5.3. Disk Diffusion
6. BY APPLICATION
6.1. Clinical Diagnostics
6.2. Drug Discovery and Development
6.3. Epidemiology
7. BY END USER
7.1. Hospitals and Diagnostic Laboratories
7.2. Pharmaceutical and Biotechnology Companies
7.3. Research and Academic Institutes
8. GEOGRAPHY
8.1. North America
8.1.1. United States
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Rest of South America
8.3. Europe
8.3.1. Germany
8.3.2. United Kingdom
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Russia
8.3.7. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle-East
8.5.1. UAE
8.5.2. Saudi Arabia
8.5.3. Turkey
8.5.4. Rest of Middle East
8.6. Africa
8.6.1. South Africa
8.6.2. Egypt
8.6.3. Rest of Africa
9. COMPETITIVE LANDSCAPE
9.1. Key Developments
9.2. Company Market Share Analysis
9.3. Product Benchmarking
10. SWOT ANALYSIS
11. COMPANY PROFILES
11.1. bioMérieux SA
11.2. Becton, Dickinson and Company
11.3. Thermo Fisher Scientific Inc.
11.4. Bio-Rad Laboratories, Inc.
11.5. Danaher Corporation (Cepheid)
11.6. Merck KGaA
11.7. Accelerate Diagnostics, Inc.
11.8. Alifax S.r.l.
11.9. Creative Diagnostics
11.10. Synbiosis (A Division of Synoptics Ltd.)
11.11. Liofilchem S.r.l.
11.12. ZHUHAI DL BIOTECH Co., Ltd (*LIST NOT EXHAUSTIVE)
12. MARKET OPPORTUNITIES
By Test Type:
Automated AST Systems
Manual AST Methods
Disk Diffusion
By Application:
Clinical Diagnostics
Drug Discovery and Development
Epidemiology
By End User:
Hospitals and Diagnostic Laboratories
Pharmaceutical and Biotechnology Companies
Research and Academic Institutes
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
